On June 17, 2025, Leiden University Medical Center (LUMC) announced that Professor Bart Roep received a prestigious European Research Council (ERC) Advanced Grant worth €2.5 million. The funding will back his team’s innovative work aimed at not just managing type 1 diabetes (T1D), but potentially curing it by making insulin-producing beta cells both stronger and “invisible” to the immune system.
In T1D, the immune system destroys the body’s own beta cells in the pancreas, which produce insulin. Without a cure, patients rely on insulin therapy, but still face long-term risks to their eyes, kidneys, and cardiovascular health. Roep’s group suggests that stressed beta cells produce a misfolded protein called DRiP, which inadvertently flags them for immune destruction. Their goal: to develop “stealth” beta cells that avoid immune detection.
The team recently identified a natural genetic variant that acts like a “steam-release valve” in the insulin gene. This variant allows beta cells to alleviate stress and avoid creating DRiP, leading to milder disease and better cell survival. By studying this variant in lab-grown beta cells derived from pluripotent stem cells (hiPSCs), the researchers aim to engineer these traits into replacement cells for transplantation. The LUMC’s GMP facility will support this effort to produce patient-ready beta cells.
Roep’s team is also developing a bionic “backpack” system to deliver medication directly to stressed beta cells. These micro-carriers would release their payload only when encountering enzyme signals from stressed beta cells, offering precision therapy without systemic effects.
Depending on genetic makeup and residual beta cell function, patients could receive either immune reprogramming (“reverse vaccination”) or transplants of engineered cells with the stealth variant. This personalized approach aims to tailor interventions to individual patient profiles .
Robert’s vision combines foundational science- identifying DRiP as an immune flag, creating stress-resistant beta cells, and developing focused drug delivery systems with the goal of translating these findings into precise, patient-specific treatments. With the ERC grant, his team now has the resources to carry this ambitious project forward, aiming to fundamentally transform the lives of individuals with type 1 diabetes.
Read more here: https://www.lumc.nl/actueel/2025/erc-advanced-grant-bart-roep/
Danish biotech start-up Fuse Vectors has launched its R&D operations in Leiden. From its new base at the Leiden Bio Science Park, the company is set to accelerate the...
LUdev is a student-run software company part of the Leiden Institute of Advanced Computer Science (LIACS) of Leiden University. The initiative gives bachelor's students the...
A month after being cleared to sell its animal-free meat fat in the US, Nourish Ingredients has set its sights on the global market with a new commercial hub in the Netherlands....